Rheumatoid Arthritis

      📢 Late breaking #2002

      ➡️In ICI-induced arthritis, patients (n=100) report worsened pain, fatigue, & physical

      Caoilfhionn Connolly CaoilfhionnMD

      11 months 1 week ago
      📢 Late breaking #2002 ➡️In ICI-induced arthritis, patients (n=100) report worsened pain, fatigue, & physical function vs population norms. ➡️High disease activity worsens symptoms #acr24 @RheumNow @jhrheumatology
      Fertility in RA. Improved outcomes in the T2T group. Abstr#1647 @RheumNow #ACR24 https://t.co/gLpY8enaEb

      Antoni Chan MD (Prof) synovialjoints

      11 months 1 week ago
      Fertility in RA. Improved outcomes in the T2T group. Abstr#1647 @RheumNow #ACR24 https://t.co/gLpY8enaEb
      Control RA, Build Stronger Bones
      11 months 1 week ago
      Shifting Trends in Initial RA Treatment Approaches

      A recent study by Sparks et al (Abstract #0509) reveals evolving tre

      Dr. John Cush RheumNow

      11 months 1 week ago
      Shifting Trends in Initial RA Treatment Approaches A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for rheumatoid arthritis (RA) over two decades in the U.S. https://t.co/6FN0WayZZR #ACR24 https://t.co/dc3CiNpKmx
      Nice data from the OTIS Autoimmune Disease in Pregnancy Project re: certolizumab-exposed pregnancies:
      - spontaneous loss

      David Liew drdavidliew

      11 months 1 week ago
      Nice data from the OTIS Autoimmune Disease in Pregnancy Project re: certolizumab-exposed pregnancies: - spontaneous loss rate comparable to non-disease controls - no stillbirths - preterm similar to disease controls Plenty positive for CZP in pregnancy! #ACR24 ABST0805 @RheumNow https://t.co/XCRYsioxC0
      A study exploring the benefits of treating RA patients to remission after achieving low disease activity (LDA).
      Key find

      Antoni Chan MD (Prof) synovialjoints

      11 months 1 week ago
      A study exploring the benefits of treating RA patients to remission after achieving low disease activity (LDA). Key findings: - Among patients initially at LDA, achieving remission (CDAI ≤2.8) led to significantly better functional outcomes and reduced durable medical equipment… https://t.co/SNPKlRieur https://t.co/YIQNMf3Oap
      RA Roundup: Is LDA Inappropriate? What about Statins for JAKs?
      11 months 1 week ago
      I have no doubt many of our RA patients will take GLP-1 agonists in the future.
      Here's some data @UCLA showing significa

      David Liew drdavidliew

      11 months 1 week ago
      I have no doubt many of our RA patients will take GLP-1 agonists in the future. Here's some data @UCLA showing significant differences in not just body weight and HbA1c, but pain. Will be fascinating to see what it does for grumbling disease activity! #ACR24 ABST2259 @RheumNow https://t.co/HdOPACEo3A
      What is #healthliteracy? Why is it important for our patients with #RMDs?

      Come to poster 1913 today at #ACR24 to find o

      Mrinalini Dey DrMiniDey

      11 months 1 week ago
      What is #healthliteracy? Why is it important for our patients with #RMDs? Come to poster 1913 today at #ACR24 to find out about health literacy & outcomes in #InflammatoryArthritis For more information on this important topic, read my article @RheumNow https://t.co/llWs5aYtpK
      heart,CV,MI.cardia,
      Addressing CV Risk in RA: Are we doing enough?
      11 months 1 week ago
      ORAL surveillance was a post-authorisation safety study of tofacitinib 5mg and 10mg versus TNF inhibitors, focusing on rates of adverse events, including MACE. A higher incidence of MACE was observed with the use of tofacitinib. Statins are recommended in patients with a history of atherosclerotic disease or 10 year predicted risk of MACE. But, how many patients with rheumatoid arthritis, at risk of MACE, are actually taking a statin?
      Instead of just JAKi, why don't we look at all our RA meds and MACE risk

      FAERS data & reporting odds ratios here: a

      David Liew drdavidliew

      11 months 1 week ago
      Instead of just JAKi, why don't we look at all our RA meds and MACE risk FAERS data & reporting odds ratios here: all the caveats of voluntary reporting, so don't put too much weight, but... prednisone. Don't forget pred is really not great for MACE! #ACR24 ABST1981 @RheumNow https://t.co/L9SlPZF2Jd
      "There's an app for that"
      but is it enough?

      US informatics national survey 2017-18:
      Rheum pts with digital health tools

      David Liew drdavidliew

      11 months 1 week ago
      "There's an app for that" but is it enough? US informatics national survey 2017-18: Rheum pts with digital health tools weren't any healthier living than those without (maybe helps exercise) It might be a conversation starter, but it's only an adjunct #ACR24 ABST1929 @RheumNow https://t.co/EZpSwm0zuP
      Always looking for cancer/CV signals from JAKi in big observational datasets w extensive JAKi usenationwide 🇯🇵 c

      David Liew drdavidliew

      11 months 1 week ago

      Always looking for cancer/CV signals from JAKi in big observational datasets w extensive JAKi use nationwide 🇯🇵 claims data RA pts n=52k (JAKi n=4.3k) Cancer with JAKi vs TNFi: aHR 2.2 (esp lung, lymphoma) This is a problem. Watch these data. #ACR24 ABST1336 @RheumNow #ACRBest https://t.co/vsnT46De6T

      Should you worry about giving TNFi to RA pts after a cancer diagnosis?

      Medicare data with colorectal, lung, prostate Ca

      David Liew drdavidliew

      11 months 1 week ago
      Should you worry about giving TNFi to RA pts after a cancer diagnosis? Medicare data with colorectal, lung, prostate Ca: TNFi pts survival no worse (numerically better) than csDMARDs Cancer pts deserve good RA treatment! #ACR24 ABST0202 Suarez-Almazor @MDAndersonNews @RheumNow https://t.co/w58MNqRt1T
      Now we have GWAS, we are getting polygenic risk scores for RA, and we can see what disease risks cluster with RA risk.

      David Liew drdavidliew

      11 months 1 week ago
      Now we have GWAS, we are getting polygenic risk scores for RA, and we can see what disease risks cluster with RA risk. RA genetic risk clusters with risk for: type 1 diabetes thyroiditis multiple sclerosis What draws these diseases together? #ACR24 ABST1365 @RheumNow https://t.co/28gU1nBEUG

      Catch up on Conference Podcasts

      ×